
    
      PRIMUS 001 is a multicentre, randomised, open label, two arm, phase II interventional trial
      with pre-clinical and translational work including in-depth molecular profiling and biomarker
      discovery/development. The primary objective is to look at the efficacy of FOLFOX-A compared
      to AG in all comers and in a biomarker positive group using progression free survival.
    
  